by Peter Ciszewski | Jan 4, 2018
Alisa Shakarian of Cambridge Biomarketing discusses the role of Advocates in rare diseases and the challenges of diagnosing rare diseases.
by Peter Ciszewski | Jan 4, 2018
Julian Adams discusses Gamida Cell’s NAM technology to develop two of its lead clinical programs by expanding blood forming stem and progenitor cells from umbilical cord blood to create highly functional, stand-alone grafts that serve as a universal bone marrow...
by Peter Ciszewski | Jan 3, 2018
Sam Falsetti, PhD of Cambridge Biomarketing discusses the film Rare in Common, which follows the experiences of rare families: their struggles, their strength, and their hope for the future as they confront the challenges of living with a rare disease. The movie has...
by Peter Ciszewski | Jan 3, 2018
Progenics Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for AZEDRA in patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma, which are rare...
by Peter Ciszewski | Dec 28, 2017
Actinium Pharmaceuticals today that the Independent Data Monitoring Committee (DMC) for the Pivotal Phase 3 SIERRA Trial (Study of Iomab-B for Elderly Relapsed or Refractory AML) of Iomab-B (131I apamistamab) completed its review of the data available from the trial...
